The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs

Expert Rev Clin Pharmacol. 2018 Oct;11(10):999-1030. doi: 10.1080/17512433.2018.1519392. Epub 2018 Sep 29.

Abstract

Most direct-acting antivirals (DAAs) and psychotropic drugs are metabolized by or induct/inhibit CYP enzymes and drug transporters. Although they are frequently coadministered, the drug-drug interactions (DDIs) have been little studied. Therefore, the aim of this review is to describe the interactions between the approved DAA or combination regimens and the main psychoactive substances, including legal and illegal drugs of abuse. Areas covered: We performed a literature search on PubMed database on drug interactions with the currently available antivirals for hepatitis C and a review of the information on pharmacokinetics, metabolism, and drug interactions from www.hep-druginteractions.org and from all the Summary of Product Characteristics (SmPC). This review covers the DDI between the DAA regimens approved, such as simeprevir and sofosbuvir, paritaprevir, glecaprevir, voxilaprevir, ombitasvir, ledipasvir, daclatasvir and sofosbuvir, elbasvir and grazoprevir, sofosbuvir and velpatasvir, glecaprevir/pibrentasvir, sofosbuvir and velpatasvir, and main psychotropic agents. Expert Commentary: DAA regimens based on sofosbuvir combination usually have less DDI than protease inhibitor-based regimens. Among protease inhibitors regimens, new combinations, such as glecaprevir/elbasvir and grazoprevir/elbasvir, seemed to have less DDI than the combination POrD (paritaprevir/ombitasvir/ritonavir/dasabuvir). However, the analysis of each interaction is theoretical and further interaction studies would be necessary to confirm actual effect.

Keywords: Antivirals; analgesics; anticonvulsants; antidepressants; antipsychotics; anxiolytics; daclatasvir; dasabuvir; direct-acting; drug interactions; drug–drug abuse; elbasvir; grazoprevir; hepatitis C; ledipasvir; ombitasvir; paritaprevir; psychotropic drugs; simeprevir; sofosbuvir; velpatasvir; voxilaprevir.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / administration & dosage
  • Antiviral Agents / adverse effects*
  • Antiviral Agents / pharmacokinetics
  • Drug Interactions
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Illicit Drugs / adverse effects
  • Illicit Drugs / pharmacokinetics
  • Psychotropic Drugs / administration & dosage
  • Psychotropic Drugs / adverse effects*
  • Psychotropic Drugs / pharmacokinetics
  • Substance-Related Disorders / complications

Substances

  • Antiviral Agents
  • Illicit Drugs
  • Psychotropic Drugs